NT-proANP and BNP in renovascular and in severe and mild essential hypertension

Kidney and Blood Pressure Research

Volumn 26, Issue 1, 2003, Pages 34-41

  Mussalo, Hanna ^a   Vanninen, Esko ^a   Ikäheimo, Risto ^a   Hartikainen, Juha ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Essential hypertension; Natriuretic peptides; Renovascular hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGING; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RENOVASCULAR HYPERTENSION; SCREENING; SYSTOLIC BLOOD PRESSURE;

ADULT; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERTENSION, RENAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0037262093     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069763     Document Type: Article

References (40)

1. Lang RE, Tholken H, Ganten D, Luft FC, Ruskoaho H, Unger T: Atrial natriuretic factor - a circulating hormone stimulated by volume loading. Nature 1985;314:264-266.
2. Ruskoaho H: Atrial natriuretic peptide: Synthesis, release, and metabolism. Pharmacol Rev 1992;44:479-602.
3. Ogawa Y, Itoh H, Nakao K: Molecular biology and biochemistry of natriuretic peptide family. Clin Exp Pharmacol Physiol 1995;22:49-53.
4. Yoshimura M, Yasue H, Ogawa H: Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Can J Physiol Pharmacol 2001;79:730-735.
5. Sangella GA, Markandu ND, Shore AC, MacGregor GA: Raised circulating levels of atrial natriuretic peptides in essential hypertension. Lancet 1986;i:179-181.
6. Sugawara A, Nakao K, Sakamoto M, Morii N, Yamada T, Itoh H, Shiono S, Imura H: Plasma concentration of atrial natriuretic polypeptide in essential hypertension. Lancet 1985;ii:1426-1427.
7. MacDonald TM, Jeffrey RF, Lee MR: Atrial natriuretic peptides in essential hypertension. Lancet 1986;i:562.
8. Needleman P, Greenwald JE: Atriopeptin: A cardiac hormone intimately involved in fluid, electrolyte, and blood pressure homeostasis. N Engl J Med 1986;314:828-834.
9. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Akioka K, Tahara A, Toda I, Takeuchi K, Kurihara N: Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992;92:29-34.
10. Buckley MG, Markandu ND, Miller MA, Sagnella GA, MacGregor GA: Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. J Hum Hypertens 1993;7:245-250.
11. Naruse M, Takeyama Y, Tanabe A, Hiroshige J, Naruse K, Yoshimoto T, Tanaka M, Katagiri T, Demura H: Atrial and brain natriuretic peptides in cardiovascular diseases. Hypertension 1994;23(1 Suppl):I231-I234.
12. Cheung BM, Brown MJ: Plasma brain natriuretic peptide and C-type natriuretic peptide in essential hypertension. J Hypertens 1994;12:449-454.
13. Takeda T, Kohno M: Brain natriuretic peptide in hypertension. Hypertens Res 1995;18:259-266.
14. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H, et al: Brain natriuretic peptide as a novel cardiac hormone in humans: Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-1412.
15. Motwani JG, McAlpine H, Kennedy N, Struthers AD: Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993;341:1109-1113.
16. Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, Suga S, Mukoyama M, Nakao K, Imura H, Sasayama S: Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993;88:372-380.
17. Schreij G, van Es PN, Schiffers PM, de Leeuw PW: Renal extraction of atrial natriuretic peptide in hypertensive patients with or without renal artery stenosis. Hypertension 1996;27:1254-1258.
18. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H: Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996;28:22-30.
19. Mussalo H, Vanninen E, Ikäheimo R, Laitinen T, Laakso M, Länsimies E, Hartikainen J: Heart rate variability and its determinants in patients with severe or mild essential hypertension. Clin Physiol 2001;21:594-604.
20. Mann SJ, Pickering TG: Detection of renovascular hypertension. State of the art: 1992. Ann Intern Med 1992;117:845-853.
21. Jonker GJ, Huisman RM, de Zeeuw D: Enhancement of screening tests for renovascular hypertension by angiotensin-converting enzyme inhibition. Nephrol Dial Transplant 1993;8:798-807.
22. Davidson RA, Wilcox CS: Newer tests for the diagnosis of renovascular disease. JAMA 1992;268:3353-3358.
23. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: The Losartan Intervention for Endpoint Reduction (LIFE) in Hypertension Study: Rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997;10:705-713.
24. Vuolteenaho O, Koistinen P, Martikkala V, Takala T, Leppaluoto J: Effect of physical exercise in hypobaric conditions on atrial natriuretic peptide secretion. Am J Physiol 1992;263:R647-R652.
25. Tahvanainen K, Länsimies E, Tikkanen P, Hartikainen J, Kärki T, Mäntysaari M: Microcomputer-based monitoring of cardiovascular functions in simulated microgravity. Adv Space Res 1992;12:227-236.
26. Vanninen E, Mustonen J, Vainio P, Länsimies E, Uusitupa M: Left ventricular function and dimensions in newly diagnosed non-insulin-dependent diabetes mellitus. Am J Cardiol 1992;70:371-378.
27. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977;55:613-618.
28. Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083.
29. Holtwick R, Gotthardt M, Skryabin B, Steinmetz M, Potthast R, Zetsche B, Hammer RE, Hertz J, Khun M: Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci USA 2002;99:7142-7147.
30. Bettencourt P, Ferreira A, Sousa T, Ribeiro L, Brandâo F, Polónia J, Cerqueira-Gomes M, Martins L: Brain natriuretic peptide as a marker of cardiac involvement in hypertension. Int J Cardiol 1999;69:169-177.
31. Lerman A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Hueblein DM, Burnett JC Jr: Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993;341:1105-1109.
32. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, Tunstall-Pedoe H, McMurray JJ, Dargie HJ: Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
33. Diamond JA, Krakoff LR, Goldman A, Coplan N, Gharavi A, Martin K, Goldsmith R, Henzlova MJ, Machac J, Phillips RA: Comparison of two calcium blockers on hemodynamics, left ventricular mass, and coronary vasodilatory in advanced hypertension. Am J Hypertens 2001;14:231-240.
34. Yasumoto K, Takata M, Ueno H, Tomita S, Tomoda F, Inoue H: Relation of plasma brain and atrial natriuretic peptides in left ventricular geometric patterns in essential hypertension. Am J Hypertens 1999;12:921-924.
35. Montorsi P, Tonolo G, Polonia J, Hepburn D, Richards AM: Correlates of plasma atrial natriuretic factor in health and hypertension. Hypertension 1987;10:570-576.
36. Yamaji T, Ishibashi M, Sekihara H, Takaku F, Nakaoka H, Fujii J: Plasma levels of atrial natriuretic peptide in primary aldosteronism and essential hypertension. J Clin Endocrinol Metab 1986;63:815-818.
37. Hirata Y, Fukui K, Dan Y, Matsuoka H, Sugimoto T, Ishii M: Renal and hormonal effects of alpha-1-adrenoceptor blockade by bunazosin in essential hypertension. Eur J Clin Pharmacol 1989;36:575-578.
38. Rascher W, Tulassay T, Lang RE: Atrial natriuretic peptide in plasma of volume-overloaded children with chronic renal failure. Lancet 1985;ii:303-305.
39. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD: Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37:1221-1227.
40. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Riegger GA, Schunkert H: Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: Evidence from a population-based study. J Am Coll Cardiol 1998;32:1839-1844.